Stephane Champiat

Stephane Champiat is a Senior Professor at The University of Texas MD Anderson Cancer Center. His research focuses on oncology, cancer immunotherapy, and immunology, with a specific emphasis on early-phase clinical trials and the development of novel therapeutic agents. His recent work includes investigating the impact of severe liver metastases on immunotherapy response, evaluating novel antibody-drug conjugates targeting CCR8⁺ regulatory T cells, and exploring the prognostic value of serum tumor markers in phase I trials. He has also published on telemedicine's role in expanding access to early-phase oncology trials, drawing on experience with over 14,000 patients.